Alpha Cognition

CIK 0001655923 · ACOG Nasdaq

SIC
2836 · Biological Products, Except Diagnostic
Type
Operating
Status
Public
Filer
Non-accelerated filer, smaller reporting company, and emerging growth company
Incorporated
British Columbia, Canada
FY End
Dec 31

Business Summary

Alpha Cognition Inc. (ACOG) is a small-cap biopharmaceutical company headquartered in Vancouver, BC (with U.S. operations in Dallas/Fort Worth, TX) focused exclusively on treatments for neurodegenerative diseases — primarily Alzheimer's disease. The company's central milestone is the FDA approval of ZUNVEYL (benzgalantamine) in July 2024 and its commercial launch in March 2025. With 71 full-time employees, Alpha Cognition is transitioning from a clinical-stage company to a commercial-stage specialty pharma with a pre-revenue base and a targeted long-term care (LTC) go-to-market strategy.

Products & Services

Commercial Product: - ZUNVEYL (benzgalantamine) — delayed-release oral tablet (5 mg, 10 mg, 15 mg), FDA-approved July 2024, launched March 2025. A next-generation acetylcholinesterase inhibitor (AChEI) with dual mechanism of action (AChE inhibition + nicotinic receptor modulation, notably alpha-7 subtype). Enteric-coated to minimize gastrointestinal side effects. Indicated for mild-to-moderate Alzheimer's disease in adults. WAC set at $820/month.

Pipeline (Pre-Clinical): - **ZUNVEYL +...

Get a free account in seconds to read the full business overview. Create free account

AI-generated summary of Item 1 (Business) from the 10-K filed Mar 31, 2026 — View filing on SEC.gov. May contain errors — refer to the filing for authoritative information.

Across SEC filings

Institutional holders · 13F

Q3 2026
42 managers reported a position for Q3 2026 +16 vs Q2 2026
Largest Q3 2026 Form 13F holders of Alpha Cognition by reported value
Largest holders Reported value
Opaleye Management Inc $29.7M
AWM Investment Company Inc $15.0M
Cable Car Capital LP $12.4M
Solas Capital Management LLC $12.3M
Ikarian Capital LLC $6.3M

Annual results · 10-K

Fiscal 2025
Revenue
$10.2M
Net loss
-$20.7M

As reported in the fiscal 2025 annual report.

Funds & ETFs · N-PORT

2 funds
Largest fund holders reported on Form N-PORT
Fund Value % of fund
Fidelity Nasdaq Composite Index Fund $132.6K < 0.01%
Avantis U.S. Small Cap Equity ETF AVSC $38.9K < 0.01%

2 funds reported holding $171.5K in total on their latest public Form N-PORT reports, the most recent dated August 2026. Security record

Securities

Securities issued by this company
CUSIP Security Type
02074J501 ACOG ALPHA COGNITION INC Common stock
02074J204 ACOGF ALPHA COGNITION INC NEW COM C Common stock

Insider trades · Form 4

+$8.35M net open-market insider transactions, last 12 months 27 filings with purchases ($8.35M), 0 filings with sales ($0)

Latest filings

5%+ holders · 13D/G

6 filers
Schedule 13D and 13G filers reporting a stake of 5% or more
Filer % of class Filed
Solas Capital Management LLC 13G 6.3% 2026-11-16
Manchester Management Company LLC 13G 7.4% 2026-09-23
Opaleye Management Inc 13G 14.2% 2026-07-24
Funicular Funds LP 13G 5.1% 2026-02-19
AWM Investment Company Inc 13G 9.9% 2026-02-13
BESSER JAMES E 13G 6.2% 2025-01-31

Latest Schedule 13D or 13G from each filer; stakes a filer has reported closed are left out.

Latest SEC filings

All filings →
Latest SEC filings by Alpha Cognition
Form Description Filed
SCHEDULE 13G/A SCHEDULE 13G/A 2026-11-16
4 Insider Transaction · Caren Deardorf 2026-11-13
3 Initial Ownership 2026-11-13
8-K CURRENT REPORT 2026-11-12
10-Q QUARTERLY REPORT 2026-11-12
4 Insider Transaction · Opaleye Management Inc. 2026-10-26
4 Insider Transaction · Opaleye Management Inc. 2026-10-19
4 Insider Transaction · Opaleye Management Inc. 2026-10-02
4 Insider Transaction · Opaleye Management Inc. 2026-09-28
SCHEDULE 13G SCHEDULE 13G 2026-09-23
Loading ownership data...
Loading insider trading data...
Loading financials...

Quality is a Plus feature

See why the score is what it is — the score history and the full test-by-test breakdown behind the composite.

Valuation is a Premium feature

What this company is worth versus its price — fair value at today's bond rate, margin of safety, and the Graham Number against the institutional consensus price.

Loading SEC filings...